Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

United Therapeutics' Asset Writedowns and Impairment history spans 5 years, with the latest figure at $4.2 million for Q4 2022.

  • For Q4 2022, Asset Writedowns and Impairment fell 95.59% year-over-year to $4.2 million; the TTM value through Sep 2024 reached $4.2 million, down 62.5%, while the annual FY2025 figure was $21.7 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2022 was $4.2 million at United Therapeutics, down from $7.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $107.3 million in Q1 2021 and bottomed at -$95.2 million in Q3 2021.
  • The 4-year median for Asset Writedowns and Impairment is $5.4 million (2020), against an average of $13.5 million.
  • The largest annual shift saw Asset Writedowns and Impairment skyrocketed 1450.0% in 2020 before it crashed 1862.96% in 2021.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at -$8.4 million in 2019, then skyrocketed by 164.29% to $5.4 million in 2020, then soared by 1662.96% to $95.2 million in 2021, then crashed by 95.59% to $4.2 million in 2022.
  • Per Business Quant, the three most recent readings for UTHR's Asset Writedowns and Impairment are $4.2 million (Q4 2022), $7.0 million (Q3 2022), and $95.2 million (Q4 2021).